MoonLake Immunotherapeutics Statistics
Share Statistics
MoonLake Immunotherapeutics has 63.47M
shares outstanding. The number of shares has increased by 0.65%
in one year.
| Shares Outstanding | 63.47M |
| Shares Change (YoY) | 0.65% |
| Shares Change (QoQ) | 0.35% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 854 |
| FTD / Avg. Volume | 0.19% |
Short Selling Information
The latest short interest is 6.1M, so 9.6% of the outstanding
shares have been sold short.
| Short Interest | 6.1M |
| Short % of Shares Out | 9.6% |
| Short % of Float | 21.56% |
| Short Ratio (days to cover) | 12.84 |
Valuation Ratios
The PE ratio is -0.03 and the forward
PE ratio is -10.6.
MoonLake Immunotherapeutics's PEG ratio is
0.
| PE Ratio | -0.03 |
| Forward PE | -10.6 |
| PS Ratio | 0 |
| Forward PS | 1.9 |
| PB Ratio | 0.01 |
| P/FCF Ratio | -29.07 |
| PEG Ratio | 0 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for MoonLake Immunotherapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.02,
with a Debt / Equity ratio of 0.
| Current Ratio | 0.02 |
| Quick Ratio | 0.02 |
| Debt / Equity | 0 |
| Debt / EBITDA | -0.02 |
| Debt / FCF | -0.02 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,206,800,020 |
| Employee Count | 100 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 282.2K |
| Effective Tax Rate | -0.23% |
Stock Price Statistics
The stock price has increased by -3.38% in the
last 52 weeks. The beta is 1.3, so MoonLake Immunotherapeutics's
price volatility has been higher than the market average.
| Beta | 1.3 |
| 52-Week Price Change | -3.38% |
| 50-Day Moving Average | 38.61 |
| 200-Day Moving Average | 45.82 |
| Relative Strength Index (RSI) | 48.52 |
| Average Volume (20 Days) | 440,700 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -143.09M |
| Net Income | -120.68B |
| EBITDA | -119.58M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1919.51 |
Full Income StatementBalance Sheet
The company has 180.43M in cash and 2.83M in
debt, giving a net cash position of 177.6M.
| Cash & Cash Equivalents | 180.43M |
| Total Debt | 2.83M |
| Net Cash | 177.6M |
| Retained Earnings | -235.59B |
| Total Assets | 511.26M |
| Working Capital | 482.28M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -116.59M
and capital expenditures -519.52K, giving a free cash flow of -117.11M.
| Operating Cash Flow | -116.59M |
| Capital Expenditures | -519.52K |
| Free Cash Flow | -117.11M |
| FCF Per Share | -1.86 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
